Sunshine Heart Inc. announced commencement of a new study examining the impact of the C-Pulse system on pulmonary circulation and right heart related to pulmonary hypertension and heart failure.

The Carillon mitral contour system is projected to be a cost-effective treatment option when compared to a typical regimen of optimal medical treatment (OMT), the present standard of care for functional mitral regurgitation (FMR).

St. Jude Medical Inc. announced that five-year results from the FAME trial have confirmed the long-term benefits of fractional flow reserve (FFR) in guiding percutaneous coronary intervention (PCI) over angiography alone.

St. Jude Medical Inc. announced primary results from the LEADLESS II study that confirm the positive benefits of the Nanostim leadless pacemaker for patients in need of a single-chamber ventricular pacemaker.

Sunshine Heart Inc. announced the U.S. Food and Drug Administration (FDA) has approved an amendment to the stopping rule criteria for the company's COUNTER HF pivotal study for its C-Pulse Heart Assist System. The agency has agreed to change this protocol from "all cause" deaths to specifically, mortality associated with device, procedure or therapy.

Extending clot-preventing dual antiplatelet therapy (DAPT) beyond the recommended 12 months after coronary stenting “should be considered” in patients at low risk for bleeding, investigators for the OPTIDUAL trial recommend.